Loading
A phase 1/2 trial of Tislelizumab, Bevacizumab in hepatocellular carcinoma and non-small-cell lung cancer, run by BeOne Medicines, now recruiting.
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT06427941 by BeOne Medicines, with 630 participants planned, started 2024-07-23 and due to reach its primary completion in 2027-03-31. Interventions recorded: BGB-B2033, Tislelizumab, Bevacizumab. Conditions listed: Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer, Extragonadal Yolk Sac Tumors. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Tislelizumab, Hepatocellular carcinoma, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares BeOne Medicines (formerly BeiGene), Tislelizumab, Small-cell lung cancer, Non-small-cell lung cancer.
Shares BeOne Medicines (formerly BeiGene), Tislelizumab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Tislelizumab, Small-cell lung cancer, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares BeOne Medicines (formerly BeiGene), Tislelizumab, Immune checkpoint inhibitors.
Shares BeOne Medicines (formerly BeiGene), Tislelizumab, Immune checkpoint inhibitors.
Shares BeOne Medicines (formerly BeiGene), Tislelizumab, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares Tislelizumab, Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/